How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Real-World Data on LUPKYNIS Use

• Aurinia Pharmaceuticals announced that five new data posters on LUPKYNIS (voclosporin) were presented in collaboration with independent investigators at the American College of Rheumatology Convergence 2025 in Chicago and the American Society of Nephrology Kidney Week 2025 in Houston.
• This collaborative release includes real-world effectiveness studies and pediatric usage insights, expanding clinical understanding of LUPKYNIS in lupus nephritis treatment.
• We’ll examine how these research presentations highlighting real-world data and pediatric use may shape Aurinia Pharmaceuticals’ investment outlook.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 38 companies in the world exploring or producing it. Find the list for free.

Aurinia Pharmaceuticals Investment Narrative Recap

Aurinia Pharmaceuticals remains focused on expanding the role of LUPKYNIS in lupus nephritis, with the investment case centered on continued revenue growth and longer-term pipeline execution. The recent release of multiple real-world data and pediatric usage studies may support short-term adoption among clinicians, but does not fundamentally shift the biggest catalyst, ongoing revenue expansion, or lessen the largest risk: heavy reliance on a single product amid competitive and exclusivity pressures.

Of the company's recent updates, the positive Phase 1 results for AUR200 stand out as an important step toward diversifying the pipeline beyond LUPKYNIS. While the new LUPKYNIS research posters reinforce confidence among prescribers, successful clinical and regulatory progress for AUR200 could become a more meaningful long-term catalyst if reliance on LUPKYNIS remains high.

By contrast, investors should be aware that patent challenges around LUPKYNIS’ exclusivity and ongoing Paragraph IV filings mean...

Read the full narrative on Aurinia Pharmaceuticals (it's free!)

Aurinia Pharmaceuticals' outlook anticipates $386.4 million in revenue and $141.3 million in earnings by 2028. This requires 14.1% annual revenue growth and a $80.7 million earnings increase from current earnings of $60.6 million.

Uncover how Aurinia Pharmaceuticals' forecasts yield a $11.71 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have set fair value estimates for Aurinia ranging from US$7.65 to US$26.67 across five perspectives. While this diversity of views exists, growing real-world data on LUPKYNIS remains a factor supporting the company’s performance, inviting you to consider multiple angles on Aurinia’s future.

Explore 5 other fair value estimates on Aurinia Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Build Your Own Aurinia Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Aurinia Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Aurinia Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Aurinia Pharmaceuticals' overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com